Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06220864 · ClinicalTrials.gov registry record · Phase 1
SNV1521 in Participants with Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Synnovation Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 9
- Study locations
NCT06220864: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Synnovation Therapeutics.
NCT06220864 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Synnovation Therapeutics. The registered enrollment target is 200 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06220864, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Synnovation Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Primary Outcome
Treatment emergent adverse events (TEAEs)
Conditions Studied
Interventions
- DRUG Trastuzumab Deruxtecan
- DRUG SNV1521
Study Locations (9)
Connecticut
- Yale University - New Haven
Pennsylvania
- Thomas Jefferson University - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- The University of Texas M.D. Anderson Cancer Center - Houston
Utah
- START Center for Cancer Care - West Valley City
New South Wales
- Scientia Clinical Research - Randwick
Queensland
- Princess Alexandra Hospital - Woolloongabba
Victoria
- The Alfred Hospital - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-02-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06220864 shows while recruiting
NCT06220864 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab Deruxtecan is the first listed.
NCT06220864 lists 9 locations in 9 states (Connecticut, Pennsylvania, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06220864 about?
NCT06220864 is a clinical study titled "SNV1521 in Participants with Advanced Solid Tumors". This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investi...
What is the current status of trial NCT06220864?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2024-02-23. Estimated completion is 2026-12.
What conditions does trial NCT06220864 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06220864?
The interventions under investigation include: Trastuzumab Deruxtecan (DRUG), SNV1521 (DRUG).
Who is sponsoring clinical trial NCT06220864?
This trial is sponsored by Synnovation Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06220864 being conducted?
This trial has 9 study locations across Connecticut, Pennsylvania, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06220864's enrollment target sits among peer trials
200 66th of 189 higher than 121 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI